A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2019 Preliminary results(data cut-off July 2019; n=35), of the Combination of Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 15 May 2019 Planned End Date changed from 1 Nov 2022 to 30 Nov 2022.
- 15 May 2019 Planned primary completion date changed from 1 Nov 2021 to 30 Nov 2021.